Recursion Pharmaceuticals
RXRX
RXRX
144 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 62 increasing their positions, 30 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
1% less funds holding
Funds holding: 146 → 144 (-2)
21% less capital invested
Capital invested by funds: $1.21B → $953M (-$257M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Holders
144
Holding in Top 10
6
Calls
$266K
Puts
$172K
Top Buyers
| 1 | +$59M | |
| 2 | +$25.6M | |
| 3 | +$24.9M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.9M |
| 5 |
BlackRock
New York
|
+$6.94M |
Top Sellers
| 1 | -$21.9M | |
| 2 | -$10.1M | |
| 3 | -$2.01M | |
| 4 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$1.32M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.14M |